Global medtech company Meril, based in Vapi, Gujarat, has announced its self-use Rapid Antigen Test for Covid-19, CoviFind, has received approval from the Indian Council of Medical Research (ICMR). This indigenously researched and developed test can detect the SARS-CoV-2 virus reliably in infectious individuals and can therefore be used for testing symptomatic individuals and immediate contacts of confirmed coronavirus cases as specified by recent ICMR guidelines.
Meril’s home-use rapid antigen tests will expand access to Covid-19 testing, while also helping the nation meet the demand for increased and frequent screening to curb the spread of Covid-19. The provision of high-quality rapid antigen testing will also enable access to screening in previously out-of-reach or under-equipped areas.